MAKING-SCIENCE
22.1.2024 16:01:32 CET | Business Wire | Press release
Making Science, a technology company specialising in innovation and digital acceleration, has today announced the launch of Gauss Cookie Deprecation Impact Tool, the first and only solution on the market designed to measure in real time what impact the loss of third-party cookies will have on companies' conversion rate to sales.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240122293551/en/
(Photo: Business Wire)
This innovative tool comes at a key moment for the industry, following the announcement of Google's elimination of third-party cookies, scheduled for the second half of 2024. The Gauss Cookie Deprecation Impact Tool will provide Making Science customers with accurate percentage data to confirm how this loss of information will affect their business. In other words, for the first time, companies will have access to an unprecedented assessment that provides real data on the percentage of users who visit websites and applications without cookies, corroborating the effect on their marketing strategies.
The tool has already yielded very significant data for a selection of Making Science clients, measuring that the absence of third-party cookies will lead to a 30% drop in their conversion rates.
Real-time data thanks to technological innovation
This new platform is essential for companies that want to be prepared for the cookieless transformation of the digital ecosystem. Thanks to technological innovation and high capabilities in data analysis, Making Science will enable organisations to effectively identify how to redesign their marketing strategies, and optimise their performance in the face of this changing landscape.
With this launch, Making Science reaffirms its pioneering position in the development of innovative technological solutions. José Antonio Martínez Aguilar, CEO and Founder of Making Science, comments: "Staying ahead in a constantly changing digital environment is not an easy task, for that, it is essential to bet on innovation every day. Undoubtedly, the key is to have the ability to anticipate and come up with solutions such as Gauss Cookie Deprecation Impact Tool. This solution not only responds to the challenge of the loss of third-party cookies, but also offers companies the opportunity to anticipate and make strategic decisions to face a new landscape based on first-party data".
Gauss, the origin of the cutting edge
This new tool from Making Science is part of Gauss, a suite of technology solutions based on First Party Data and Artificial Intelligence for decision-making in key marketing and sales processes.
About Making Science
Making Science is a digital acceleration company with more than 1200 employees and a presence and technological development in 14 markets: Spain, Portugal, Mexico, Colombia, France, Italy, UK, Ireland, Sweden, Denmark, Norway, Germany, Georgia and USA. As a consulting partner of Local Planet, the world's largest network of independent media agencies, Making Science offers digital, technology and performance marketing services to an international audience. The areas in which Making Science operates are digital marketing and MarTech, software and cloud and artificial intelligence and SaaS, with a firm commitment to innovation.
As part of its commitment to innovation, Making Science offers its clients end-to-end capabilities required for consulting, development, integration and maintenance of advanced IT solutions that offer maximum scalability, cost-effectiveness and efficiency. In addition, it has a global network of delivery hubs that drive job creation and the availability of highly qualified technological talent for the development of projects that accelerate transformation and modernization.
Making Science participates in various ESG initiatives, including the Climate Pledge, the United Nations Global Compact and the Pledge1% initiative, supporting non-profit organisations in its community with a strong commitment that will have a great impact in the future.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240122293551/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom